Policy - STAT

Politics By Lev Facher, Nicholas Florko, Andrew Joseph, and Kate Sheridan

Doctors in Congress, new e-cigarette taxes, stem cells, and abortion rights: Here’s what STAT is watching tonight

Politics By Lev Facher

Will Fauci have a job? Will the public regain trust in the FDA? 8 of the scientific institutions and traditions on the line on Tuesday

D.C. Diagnosis By Nicholas Florko

Will this be the most-watched FDA meeting ever?

Pharmalot By Ed Silverman

Pharma contributed to attorneys general who want to repeal the Affordable Care Act

First Opinion By Elizabeth O'Day

Cutting off H-1B visas will hurt the biopharma industry

Politics By Nicholas Florko

‘Are you an American, sir?’: Lawmakers interrogate Amgen, Novartis, Mallinckrodt executives on why U.S. prices are so high

Politics By Nicholas Florko

‘You just got better at making money’: Democrats blast Celgene, Teva for price hikes detailed in internal documents

Politics By Nicholas Florko

Congressional investigation reveals Celgene, Teva plotted to keep drug prices high

Politics By Lev Facher

Trump’s debate highlights his hunger for a rushed, election-eve vaccine approval

Politics By Nicholas Florko

Drug industry CEOs will testify this week about some of pharma’s most controversial medicines

First Opinion By Laura E. Riley and Brenna L. Hughes

Pregnant and lactating women should not be excluded from Covid-19 drug, vaccine trials

D.C. Diagnosis By STAT staff

STAT+ Conversations: The D.C. Diagnosis

Politics By Lev Facher

Biden-aligned group outlines potential Day 1 drug pricing actions

First Opinion By Luciana Borio and Jesse L. Goodman

A vaccine alone won’t stop Covid-19. We also need a trusted plan for it

Politics By Nicholas Florko and Lev Facher

Trump’s last-ditch drug pricing moves could help him in November. But they likely won’t save Americans money

Politics By Nicholas Florko

With election looming, Trump releases major, last-ditch drug pricing order

Politics By Lev Facher

A Senate race in Kansas between two doctors sets the stage for an election hyper-focused on health policy — and on Covid-19

First Opinion By Josephine Johnston

The U.S. must do some heavy lifting to prepare for heritable genome editing

Politics By Nicholas Florko

How Trump could use a rare regulatory maneuver to lower drug prices before Election Day, and how it could backfire

First Opinion By Stephen Patrick

The lack of a national policy agenda for children during Covid-19 — and beyond — causes grave harm

Politics By Nicholas Florko

New poll shows wide support for several Trump drug pricing reforms, but not rebate changes

Health By Lev Facher

Trump pledges a Covid-19 vaccine by end of 2020 — without acknowledging the scientific uncertainty

Politics By Nicholas Florko

Drug industry lobbyists circulate two drug pricing proposals in hopes of warding off a Trump executive order

Politics By Nicholas Florko and Lev Facher

As Covid-19 pressures mount, political newcomer Stephen Hahn struggles to protect an FDA under siege

Exclusive By Nicholas Florko and Lev Facher

Most Read

Trump wasn’t always so linguistically challenged. What could explain the change?

Failure to warn: Hundreds died while taking an arthritis drug, but nobody alerted patients

‘A number of new stars’: The definitive guide to the Trump administration’s coronavirus response team

Rick Bright, Trump administration vaccine expert turned whistleblower, resigns NIH post

9 ways Covid-19 may forever upend the U.S. health care industry

Trump promises seniors $200 prescription drug gift certificates, but questions abound

FDA to require strong warnings about combining pain pills with anxiety medication

The surgeon general and his brother: A family’s painful reckoning with addiction

All Coverage

Doctors in Congress, new e-cigarette taxes, stem cells, and abortion rights: Here’s what STAT is watching tonight

Will Fauci have a job? Will the public regain trust in the FDA? 8 of the scientific institutions and traditions on the line on Tuesday

Will this be the most-watched FDA meeting ever?

Pharma contributed to attorneys general who want to repeal the Affordable Care Act

Cutting off H-1B visas will hurt the biopharma industry

‘Are you an American, sir?’: Lawmakers interrogate Amgen, Novartis, Mallinckrodt executives on why U.S. prices are so high

‘You just got better at making money’: Democrats blast Celgene, Teva for price hikes detailed in internal documents

Congressional investigation reveals Celgene, Teva plotted to keep drug prices high

Trump’s debate highlights his hunger for a rushed, election-eve vaccine approval

Drug industry CEOs will testify this week about some of pharma’s most controversial medicines

Pregnant and lactating women should not be excluded from Covid-19 drug, vaccine trials

STAT+ Conversations: The D.C. Diagnosis

Biden-aligned group outlines potential Day 1 drug pricing actions

A vaccine alone won’t stop Covid-19. We also need a trusted plan for it

Trump’s last-ditch drug pricing moves could help him in November. But they likely won’t save Americans money

With election looming, Trump releases major, last-ditch drug pricing order

A Senate race in Kansas between two doctors sets the stage for an election hyper-focused on health policy — and on Covid-19

The U.S. must do some heavy lifting to prepare for heritable genome editing

How Trump could use a rare regulatory maneuver to lower drug prices before Election Day, and how it could backfire

The lack of a national policy agenda for children during Covid-19 — and beyond — causes grave harm

New poll shows wide support for several Trump drug pricing reforms, but not rebate changes

Trump pledges a Covid-19 vaccine by end of 2020 — without acknowledging the scientific uncertainty

Drug industry lobbyists circulate two drug pricing proposals in hopes of warding off a Trump executive order

As Covid-19 pressures mount, political newcomer Stephen Hahn struggles to protect an FDA under siege

PhRMA scrambles to respond to Trump’s drug pricing ultimatum, as Monday deadline looms